From Motley Fool:
Despite the ongoing political storm over U.S. prescription drug prices, major drug manufacturers — or “Big Pharma” — remain, on balance, an attractive group of equities for long-term investors. The fact of the matter is that major pricing reforms aren’t even on the political radar for either party at this point, and the pharma industry has multiple tailwinds working in its favor.